These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia.
    Author: Zhu B, Ascher-Svanum H, Shi L, Faries D, Montgomery W, Marder SR.
    Journal: Psychiatr Serv; 2008 Mar; 59(3):315-7. PubMed ID: 18308914.
    Abstract:
    OBJECTIVE: This study compared the time to discontinuation for any reason of first-generation antipsychotics--in oral versus depot formulation--in the usual care of schizophrenia. METHODS: This study used data from a three-year, prospective, nonrandomized, noninterventional, multisite study of schizophrenia. Participants initiated on oral haloperidol or fluphenazine (N=202) were compared with those initiated on haloperidol or fluphenazine in depot formulation (N=97) on time to all-cause discontinuation for one year after initiation, by using Kaplan-Meier survival analysis, a Cox proportional hazards regression model, and propensity score-adjusted bootstrap resampling methods. RESULTS: Compared with participants treated with the oral formulation, those treated with depot first-generation antipsychotics had a significantly longer mean time to all-cause medication discontinuation and were twice as likely to stay on the medication. CONCLUSION: In the usual care of schizophrenia, treatment with first-generation antipsychotics in depot formulation appears to be associated with longer time to all-cause medication discontinuation compared with oral formulation of the same medication.
    [Abstract] [Full Text] [Related] [New Search]